The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules

Immunological Reviews

Volumn 172, Issue , 1999, Pages 267-278

  Kropshofer, Harald ^a   Hämmerling, Günter J ^a   Vogt, Anne B ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HLA D ANTIGEN; HLA DM ANTIGEN; HLA DQ ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033452836     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01371.x     Document Type: Review

References (89)

1. 1. Kelly AP, Monaco JJ, Cho S, Trowsdale J. A new human HLA class II-related locus. Nature 1991;353:571-573.
2. 2. Cho S, Attaya M, Monaco JJ. New class II-like genes in the murine MHC. Nature 1991;353:573-576.
3. 3. Sanderson F, Powis SH, Kelly AP, Trowsdale J. Limited polymorphism in HLA-DM does not involve the peptide binding groove. Immunogenetics 1994;39:56-58.
4. 4. Kern I, Steimle V, Siegrist CA, Mach B. The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes. Int Immunol 1995;7:1295-1299.
5. 5. Westerheide SD, Louis-Plence P, Ping D, He XF, Boss JM. HLA-DMA and HLA-DMB expression functions through the conserved S-X-Y region. J Immunol 1997;158:4812-4821.
6. 6. Chang C-H, Guerder S, Hong S-C, van Ewijk W, Flavell RA. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 1996;4:167-178.
7. 7. Fling SP, Rak J, Muczynski KA, Arp B, Pious D. Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p. J Exp Med 1997;186:1469-1480.
8. 8. Mosyak L, Zaller DM, Wiley DC. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 1998;9:377-383.
9. 9. Fremont DH, Crawford F, Marrack P, Hendrickson WA, Kappler J. Crystal structure of mouse H2-M. Immunity 1998;9:385-393.
10. 10. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997;6:293-302.
11. 11. Zheng Z, Castano AR, Segelke BW, Stura EA, Peterson PA, Wilson IA. Crystal structure of mouse CD1 : an MHC-like fold with a large hydrophobic binding groove. Science 1997;277:339-345.
12. 12. Burmeister WP, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor. Nature 1994;372:336-343.
13. 13. Marks MS, Roche PA, van Donselaar E, Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the β chain directs HLA-DM to MHC class II compartments. J Cell Biol 1995;131:351-369.
14. 14. Lindstedt R, Liljedahl M, Péléraux A, Peterson PA, Karlsson L. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 1995;3:561-572
15. 15. Marks, MS, Ohno H, Kirchhausen T, Bonifacino JS. Protein sorting by tyrosine-based signals: adapting to the Ys and wherefores. Trends Cell Biol 1997;7:124-118.
16. 16. Peters PJ, Neefjes JJ, Oorschot V, Ploegh HL, Geuze HJ. Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature 1991;349:669-676.
17. 17. Neefjes J. CIIV, MIIC and other compartments for MHC class II loading. Eur J Immunol 1999;29:1421-1425.
18. 18. Sanderson F, et al. Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science 1994;266:1566-1569.
19. 19. Karlsson L, Peleraux A, Lindstedt R, Liljedahl M, Peterson PA. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science 1994;266:1569-1572
20. 20. Denzin LK, Robbins NF, Carboy-Newcomb C, Cresswell P. Assembly and intracellular transport of HLA-DM and correction of the class II antigen-processing defect in T2 cells. Immunity 1994;1:595-606.
21. 21. Mellins E, Smith L, Arp B, Cotner T, Celis E, Pious D. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 1990;343:71-74.
22. 22. Ceman S, Rudersdorf R, Long EO, Demars R. MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability. J Immunol 1992;149:754-761
23. 23. Riberdy JM, Newcomb JR, Surman MJ, Barbosa JA, Cresswell P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 1992;360:474-477.
24. 24. Bakke O, Dobberstein B. MHC class II-associated invariant chain contains a sorting signal for endosomal compartments. Cell 1990;63:707-715.
25. 25. Lotteau V, et al. Intracellular transport of class II MHC molecules directed by the invariant chain. Nature 1990;348:600-605.
26. 26. Morris P, et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551-554.
27. 27. Fling SP, Arp B, Pious D. The HLA-DMA gene is required for the formation of stable class II/peptide complexes. Nature 1994;368:554-558.
28. 28. Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc Natl Acad Sci USA 1996;93:9724-9729.
29. 29. Sette A, et al. Invariant chain peptides in most HLA-DR molecules of an antigen processing mutant. Science 1992;258:1801-1804.
30. 30. Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ. Self-release of CLIP in peptide loading of HLA-DR molecules. Science 1995;270:1357-1359.
31. 31. Avva R, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994;1:763-774.
32. 32. Sloan VS, et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 1995;375:802-806.
33. 33. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 1995;82:155-165.
34. 34. Sherman MA, Weber DA, Jensen P. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptides. Immunity 1995;3:197-205.
35. 35. Buus S, Sette A, Colon SM, Jenis DM, Grey HM. Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell 1986;47:1071-1077.
36. 36. Neefjes JJ, Ploegh HL. Intracellular transport of MHC class II molecules. Immunol Today 1992;13:179-184.
37. 37. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996;4:87-96.
38. 38. Sadegh-Nasseri S. Germain RN. A role for peptide in determining MHC class II structure. Nature 1991;353:167-170
39. 39. Stern LJ, Wiley DC. The human MHC class II protein HLA-DR1 assembles as empty αβ-heterodimers in the absence of antigenic peptide. Cell 1992;68:465-477.
40. 40. Germain R, Rinker Jr AG. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes selective cell surface expression of occupied molecules. Nature 1993;363:725-728
41. 41. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 1996;184:2153-2165.
42. 42. Germain R, Hendrix LR. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 1991;353:134-139.
43. 43. Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ. Editing of the HLA-DR peptide repertoire by HLA-DM. EMBO J 1996;15:6144-6154.
44. 44. Ellis RJ, Hemmingsen SM. Molecular chaperones: proteins essential for the biogenesis of some macromolecular structures. Trends Biochem Sci 1989;14:339-342.
45. 45. Deng H, et al. Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease. J Exp Med 1993;178:1675-1680.
46. 46. Lindner R, Unanue ER. Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J 1996;15:6910-6920.
47. 47. Katz JF, Stebbins C, Appella E, Sant AJ. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J Exp Med 1996;184:1747-1753.
48. 48. Kropshofer H, Vogt AB, Hämmerling GJ. Structural features of invariant chain CLIP region controlling rapid release from HLA-DR molecules and inhibition of peptide binding. Proc Natl Acad Sci USA 1995;92:8313-8317.
49. 49. Weber DA, Evavold BD, Jensen PE. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 1996;274:618-620.
50. 50. Stern LJ, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-221.
51. 51. Van Ham SM, Grüneberg U, Malcharek G, Broker I, Melms A, Trowsdale J. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs. J Exp Med 1996;184:2019-2024.
52. 52. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
53. 53. Kropshofer H, Hämmerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997;18:77-82.
54. 54. Radrizzani L, et al. Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM. Eur J Immunol 1999;29:660-668.
55. 55. Ullrich HJ, Doring K, Gruneberg U, Jahnig F, Trowsdale J, van Ham SM. Interaction between HLA-DM and HLA-DR involves regions that undergo conformational changes at lysosomal pH. Proc Natl Acad Sci USA 1997;94:13163-13168
56. 56. Mellins E, et al. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides. J Exp Med 1994;179:541-549.
57. 57. Kovats S, et al. Invariant chain-independent function of H-2M in the formation of endogenous peptide-major histocompatibility complex class II complexes in vivo. J Exp Med 1998;187:245-251.
58. 58. Swier K, Brown DR, Bird JJ, Martin DW, Van Kaer L, Reiner SL. A critical, invariant chain independent role for H2-M in antigen presentation. J Immunol 1998;160:540-544.
59. 59. Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995;375:603-606.
60. 60. Nadimi F, et al. Antigen presentation of hen egg-white lysozyme but not of ribonuclease A is augmented by the major histocompatibility complex class II-associated invariant chain. Eur J Immunol 1991;21:1255-1263.
61. 61. Pinet V, Malnati MS, Long EO. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. J Immunol 1994;152:4852-4560.
62. 62. Adorini L, Appella E, Doria G, Cardinaux F, Nagy ZA. Competition for antigen presentation in living cells involves exchange of peptides bound by class II MHC molecules. Nature 1989;342:800-803.
63. 63. Miyazaki T, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 1996;84:531-542.
64. 64. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 1996;84:543-550.
65. 65. Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol 1998;28:2605-2618.
66. 66. Griffin JP, Chu R, Harding CV. Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. J Immunol 1997;158:1523-1532.
67. 67. Pinet VM, Long EO. Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. Eur J Immunol 1998;28:799-804.
68. 68. Accapezzato D, et al. Generation of an MHC class II-restricted T cell epitope by extracellular processing of hepatitis δ antigen. J Immunol 1998;160:5262-5266.
69. 69. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. Accumulation of long-lived peptide-MHC class II complexes induced in dendritic cells by inflammatory stimuli. Nature 1997;388:782-787.
70. 70. Amoscato AA, Prenovitz DA, Lotze MT. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 1998;161:4023-4032.
71. 71. Tonelle C, DeMars R, Long EO. DOβ: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J 1985;4:2839-2847.
72. 72. Servenius B, Rask L, Peterson PA. Class II genes of the human major histocompatibility complex. The DOβ gene is a divergent member of the class II β gene family. J Biol Chem 1987;262:8759-8766.
73. 73. Trowsdale J, Kelly A. The human HLA class II α chain gene DZ α is distinct from genes in the DP, DQ and DR subregions. EMBO J 1985;4:2231-2237.
74. 74. Liljedahl M, Kuwana T, Fung-Leung W-P, Jackson MR, Peterson PA, Karlsson L. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J 1996;15:4817-4824.
75. 75. Douek DC, Altmann DM. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int Immunol 1997;9:355-364.
76. 76. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 1997;278:106-109.
77. 77. Kropshofer H, et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998;17:2971-2981.
78. 78. Ponzoni M, Guarnaccia F, Corrias MV, Cornaglia-Ferraris P. Uncoordinate induction and differential regulation of HLA class-I and class-II expression by γ -interferon in differentiating human neuroblastoma cells. Int J Cancer 1993;55:817-823.
79. 79. Van Ham SM, et al. HLA-DO is a negative modulator of HLA-DM mediated MHC class II peptide loading. Curr Biol 1997;7:950-957.
80. 80. Liljedahl M, et al. Altered antigen presentation in mice lacking H2-O. Immunity 1998;8:233-243.
81. 81. Angelisova P, Hilgert I, Horejsi V. Association of four antigens of the tetraspan family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. Immunogenetics 1994;39:249-256.
82. 82. Szollosi J, Horejsi V. Bene L, Angelisova P, Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996;157:2939-2946.
83. 83. Rubinstein E, Le Naour F, Lagaudriere-Gesbert C, Billard M, Conjeaud H, Boucheix C. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J Immunol 1996;26:2657-2665.
84. 84. Levy S, Todd SC, Maecker HAT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998;16:89-109.
85. 85. Hammond C, Denzin LK, Pan M, Griffith JM, Geuze HJ, Cresswell P. The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules. J Immunol 1998;161:3282-3291.
86. 86. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998;273:20121-20127.
87. 87. Monks CRF, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82-86.
88. 88. Horejsi V, Drbal K, Angelisova P. A clustered subset of MHC class II molecules. Immunol Today 1998;19:486.
89. 89. Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 1993;14:349-352.